ET019003-T Cells

N/A

Report date: 2024/12/23 15:37:39

Base Information

Drug NameET019003-T Cells
Drug Alias NameAnti-CD19 immunotherapy - Eureka TherapeuticsAnti-CD19 chimeric antigen receptor T cell therapy - Eureka TherapeuticsET-019003
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesEureka Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEureka(Beijing) Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsLymphomaLeukemia

Other Information

ATC CodeN/A
Related LinksN/A